Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

Nivolumab

  • You have access
    Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
    MARTIN SVATON, MONIKA BRATOVA, LEONA KOUBKOVA, ONDREJ FISCHER, BOHUSLAV MELICHAR, MICHAL HRNCIARIK, DANIEL DOLEZAL, ONDREJ BILEK, JANA KREJCI, MARIE DROSSLEROVA, ZDENKA DLOUHA, JIRI BLAZEK, PETRA MAJKOVA, LUCIE BROZOVA and MAREK STASTNY
    Anticancer Research April 2022, 42 (4) 1987-1995; DOI: https://doi.org/10.21873/anticanres.15677
  • You have access
    Efficacy of a Flat Low Dose of Nivolumab in Advanced Cancer: A Retrospective Case Series
    SOFIE JORIS, CHRISTEL FONTAINE, LORE DECOSTER, JACQUES VANDERAUWERA, KRIS THIELEMANS, WIM WAELPUT and JACQUES DE-GRĂˆVE
    Anticancer Research March 2022, 42 (3) 1433-1437; DOI: https://doi.org/10.21873/anticanres.15613
  • You have access
    Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?
    CHIARA CICCARESE, ROBERTO IACOVELLI, SEBASTIANO BUTI, FRANCESCA PRIMI, SERENA ASTORE, FRANCESCO MASSARI, MIRIAM GRAZIA FERRARA, GIUSEPPE PALERMO, NAZARIO FOSCHI, VALERIO IACOVELLI, ERNESTO ROSSI, GIOVANNI SCHINZARI, PIERLUIGI BOVE, PIERFRANCESCO BASSI, EMILIO BRIA and GIAMPAOLO TORTORA
    Anticancer Research March 2022, 42 (3) 1487-1493; DOI: https://doi.org/10.21873/anticanres.15620
  • You have access
    Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab
    HIDEAKI SUEMATSU, KAZUKI KANO, TAKANOBU YAMADA, ITARU HASHIMOTO, HAYATO WATANABE, KOSUKE TAKAHASHI, MAMORU WATANABE, KEI HAYASHI, YOSHIHIRO KANETA, MITSUHIRO FURUTA, YASUHIRO INOKUCHI, NOZOMU MACHIDA, TORU AOYAMA, HIROSHI TAMAGAWA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA, TAKASHI OGATA and TAKASHI OSHIMA
    Anticancer Research March 2022, 42 (3) 1535-1540; DOI: https://doi.org/10.21873/anticanres.15626
  • You have access
    PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer
    TATSUYA ITO, ISAKU OKAMOTO, KUNIHIKO TOKASHIKI, HIROKI SATO, TAKURO OKADA, GAI YAMASHITA, TOSHITAKA NAGAO, HIDEAKI HIRAI, NATSUKI SAIGUSA and KIYOAKI TSUKAHARA
    Anticancer Research March 2022, 42 (3) 1547-1554; DOI: https://doi.org/10.21873/anticanres.15628
  • You have access
    Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma
    TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KUNIHIKO TOKASHIKI, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, YUSUKE AIHARA, KENJI HANYU, YUKIOMI KUSHIHASHI, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, YUKI HARADA, KAHO MOMIYAMA, TAKU YAMASHITA, GO OMURA, HIDEAKI TAKAHASHI, NOBUHIKO ORIDATE and KIYOAKI TSUKAHARA
    Anticancer Research March 2022, 42 (3) 1607-1613; DOI: https://doi.org/10.21873/anticanres.15635
  • You have access
    A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma
    RENPEI KATO, TAKAHIRO KOJIMA, TOMOKAZU SAZUKA, HAYATO YAMAMOTO, SHOHEI FUKUDA, KAZUTOSHI YAMANA, YUSUKE SUGINO, SHUZO HAMAMOTO, NOBORU NAKAIGAWA, KOKI KABU, HIROSHI MURAKAMI and WATARU OBARA
    Anticancer Research December 2021, 41 (12) 6199-6209; DOI: https://doi.org/10.21873/anticanres.15439
  • You have access
    Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series
    HIROSHI AOKI, NAOKI MATSUMOTO, HIROSHI TAKAHASHI, MASAYUKI HONDA, TOMOHIRO KANEKO, SHUHEI ARIMA, TOMOTAKA ISHII, TAKU MIZUTANI, RYOTA MASUZAKI, KAZUSHIGE NIREI, HIROAKI YAMAGAMI, MASAHIRO OGAWA, TATSUO KANDA, MITSUHIKO MORIYAMA and KATSUHIRO MIURA
    Anticancer Research December 2021, 41 (12) 6225-6230; DOI: https://doi.org/10.21873/anticanres.15442
  • You have access
    Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients
    YUKIKO SHIMODA, TATSUYA YOSHIDA, MASAYUKI SHIRASAWA, TAKAAKI MIZUNO, HITOMI JO, YUJI MATSUMOTO, YUKI SHINNO, YUSUKE OKUMA, YASUSHI GOTO, HIDEHITO HORINOUCHI, NOBORU YAMAMOTO, YASUSHI YATABE, YUICHIRO OHE and NORIKO MOTOI
    Anticancer Research November 2021, 41 (11) 5739-5747; DOI: https://doi.org/10.21873/anticanres.15390
  • You have access
    Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
    TAIGO KATO, AKIRA NAGAHARA, NORIHIKO KAWAMURA, WATARU NAKATA, TETSUJI SODA, KYOSUKE MATSUZAKI, KOJI HATANO, ATSUNARI KAWASHIMA, TAKESHI UJIKE, RYOICHI IMAMURA, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA, SEIJI YAMAGUCHI, TETSUYA TAKAO, YASUTOMO NAKAI, MASASHI NAKAYAMA, NORIO NONOMURA and MOTOHIDE UEMURA
    Anticancer Research November 2021, 41 (11) 5811-5816; DOI: https://doi.org/10.21873/anticanres.15398

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire